Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (331-340 of 703) with videos related to

Pageof 71
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
The Journal of Clinical Investigation|May 29, 2014
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitorsJamie N Anastas, Rima M Kulikauskas, Tigist Tamir, et al.
The Journal of Clinical Investigation|November 20, 2025
Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humansLinda Wu, John M Wentworth, Christopher Liddle, et al.
Psycho-Oncology|December 18, 2024
Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods StudyKathy Dempsey, Robyn Saw, Iris Bartula, et al.
Cancer Immunology Research|August 14, 2021
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced MelanomaF Stephen Hodi, Jedd D Wolchok, Dirk Schadendorf, et al.
Pathology|March 30, 2016
The molecular profile of metastatic melanoma in AustraliaMegan Lyle, Lauren E Haydu, Alexander M Menzies, et al.
The Journal of Investigative Dermatology|September 23, 2014
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomasJinhua Wang, Sharon K Huang, Diego M Marzese, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Frontiers in Immunology|June 28, 2021
<i>PDCD1</i> Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic MelanomaSagun Parakh, Ashan Musafer, Sabrina Paessler, et al.
Journal for Immunotherapy of Cancer|May 8, 2020
Efficacy of immune checkpoint inhibitors for in-transit melanomaEmilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, et al.
Pageof 71

Showing results (331-340 of 703) with videos related to

Sort By:
Pageof 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
The Journal of Clinical Investigation|May 29, 2014
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitorsJamie N Anastas, Rima M Kulikauskas, Tigist Tamir, et al.
The Journal of Clinical Investigation|November 20, 2025
Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humansLinda Wu, John M Wentworth, Christopher Liddle, et al.
Psycho-Oncology|December 18, 2024
Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods StudyKathy Dempsey, Robyn Saw, Iris Bartula, et al.
Cancer Immunology Research|August 14, 2021
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced MelanomaF Stephen Hodi, Jedd D Wolchok, Dirk Schadendorf, et al.
Pathology|March 30, 2016
The molecular profile of metastatic melanoma in AustraliaMegan Lyle, Lauren E Haydu, Alexander M Menzies, et al.
The Journal of Investigative Dermatology|September 23, 2014
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomasJinhua Wang, Sharon K Huang, Diego M Marzese, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Frontiers in Immunology|June 28, 2021
<i>PDCD1</i> Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic MelanomaSagun Parakh, Ashan Musafer, Sabrina Paessler, et al.
Journal for Immunotherapy of Cancer|May 8, 2020
Efficacy of immune checkpoint inhibitors for in-transit melanomaEmilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, et al.
Pageof 71